Newer drugs for refractory and relapsed multiple myeloma are effective but costly, review finds

Several newer generation drugs used to treat relapsed and refractory multiple myeloma offer slightly improved health outcomes but would need to be substantially discounted to be cost effective, a review by an independent non-profit US institute has concluded.1